ADVERTISEMENT
If successful, the researchers plan to extend testing to children with congenital tooth deficiency, starting with patients aged two to seven who have been missing at least four teeth since birth.
“We aim to provide relief to those suffering from tooth loss or absence,” said lead researcher Katsu Takahashi to The Mainichi. “While no treatment to date offers a permanent solution, there is high hope for tooth regeneration.”
Should these trials prove effective, the drug could become widely available within six years. It has the potential to benefit patients with congenital deficiencies and those who have lost teeth due to injury or decay.
ADVERTISEMENT
